Rallybio Corp (RLYB) Form 8-K — Nov 4, 2026
Rallybio stockholders overwhelmingly approved all eight proposals at the November 4, 2026 annual meeting, clearing the path for the reverse merger with Avenzo Therapeutics expected to close on November 6, 2026. The share issuance to Avenzo securityholders was approved under Nasdaq rules 5635(a) and (b), representing more than 20% of pre-merger shares and resulting in a change of control. The company also declared an $83.6 million special cash distribution, or $13.90 per share, payable to holders of record as of November 5, 2026, with payment beginning November 13, 2026.
Key figures
- Cash Position
- 0
- Expected merger close
- 2026-11-06
- Authorized share increase
- 200,000,000 to 500,000,000
- Distribution payment date
- 2026-11-13
- Expected ex dividend date
- 2026-11-09
- Reverse split ratio range
- 1-for-2 to 1-for-9
- Cash distribution per share
- 13.9
- Cash distribution total usd
- 83600000
- Shares outstanding record date
- 5312584
- Equity plan initial share reserve
- 18% of shares outstanding post-merger
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.